{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Adverse events be summarized based on the Common Toxicity Criteria version 4.0.","groups":[{"description":"This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).","id":"OG000","title":"Buparlisib (BKM120)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}